This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MEF2A / Myocyte-specific enhancer factor 2A · IHC design guide
Design Immunohistochemistry for MEF2A
Plan MEF2A paraffin IHC around nuclear staining (HPA tissue IHC). Use high-staining cardiomyocytes as a positive control and liver cholangiocytes, where staining was not detected, as a comparison (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MEF2A Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | General nuclear staining across cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9953) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | Liver+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent between sections (standard IHC practice; not target-specific) | |
| Caveat | Staining shows medium agreement with RNA (HPA tissue IHC) | |
| Regulation | MEF2/MEFA: skeletal muscle, heart, brain (UniProt) | |
| Isoform / epitope | 8 isoforms; antibody epitope coverage is unreported (UniProt; datasheet PB9953) |
Section 1
Recommended MEF2A IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet: PB9953) is accompanied by four published MEF2A IHC protocols (PMC5415962; PMC11654142; PMC9715834; PMC5759946).
| Sample | Paraffin-embedded mouse brain tissue; fixative not specified (datasheet PB9953) |
| Fixation | Image fixative and duration unreported (datasheet PB9953); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9953); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9953) |
| Primary antibody | Rabbit anti-MEF2A, 0.5-1μg/ml (datasheet PB9953) |
| Primary incubation | Overnight at 4 °C (datasheet PB9953) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9953) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MEF2A-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet: PB9953). Use the stated retrieval conditions when reproducing a published protocol (PMC5415962; PMC11654142; PMC5759946).
Section 2
What Is the Expected MEF2A Staining Pattern?
MEF2A is a nuclear transcription factor with no transmembrane segment (UniProt Q02078: location, topology). In paraffin section IHC, expect nuclear staining in cells reported as high by HPA, including cardiomyocytes, cerebellar granular layer cells, and cerebral cortical neurons (HPA: High in each). HPA describes general nuclear expression, but rates its tissue IHC evidence Approved with medium consistency between staining and RNA data (HPA: tissue IHC).
| Distinct nuclear staining in cardiomyocytes or cerebellar granular layer cells (HPA: High in both). | This matches the expected compartment and reported positive cell types (UniProt Q02078: nucleus; HPA: general nuclear expression). Compare nuclei with adjacent tissue structures and the counterstain; judge the pattern within each cell type rather than treating every brown area as positive (general IHC practice). |
| Predominantly cytoplasmic chromogen with little nuclear signal in an otherwise positive tissue (HPA: general nuclear expression). | That is discordant with the IHC pattern and UniProt location (HPA: tissue IHC; UniProt Q02078: nucleus). Investigate staining artefact and antibody specificity. HPA also reports uncertain cytosolic localisation by ICC-IF, so cytoplasmic colour alone cannot establish a true IHC signal (HPA: subcellular). |
| Strong staining in liver cholangiocytes or stomach glandular cells (HPA: Not detected in both). | The result conflicts with those HPA cell-level observations and warrants checks for cross-reactivity or endogenous chromogenic activity (HPA: tissue IHC; general IHC practice). “Not detected” describes the reported samples and assay; it is not proof that every such cell must always be negative. |
| Broad colour across cells, spaces, or slide areas without discernible nuclei (HPA: general nuclear expression). | Treat this as background until a nuclear pattern survives comparison with the negative control (general IHC practice). Uneven blocking, excess antibody, or detection background are possible workflow causes (general IHC practice); the supplied HPA and UniProt records do not assign a MEF2A-specific cause. |
| No nuclear signal in heart cardiomyocytes or cerebral cortical neurons (HPA: High in both). | A missing signal in these reported positive cells raises a failed-assay or low-sensitivity question (HPA: tissue IHC; general IHC practice). Confirm tissue identity and control performance before interpreting the absence biologically; HPA’s Approved rating has only medium staining–RNA consistency (HPA: tissue IHC). |
💡Expected MEF2A appearanceCall a result positive when identifiable cardiomyocyte or neuronal nuclei show clear chromogenic staining above background (HPA: High in heart cardiomyocytes and cerebral cortical neurons; UniProt Q02078: nucleus); diffuse non-nuclear colour alone is suspect (HPA: general nuclear expression; general IHC practice).
| Cell and tissue choice (HPA: tissue IHC). | HPA reports High staining in adipocytes, adrenal glandular cells, cerebellar granular layer cells, cortical neurons, esophageal squamous cells, cardiomyocytes, and lung alveolar cells (HPA: High in each). It reports Not detected in liver cholangiocytes and stomach glandular cells (HPA: tissue IHC). These are useful comparison contexts, not universal controls. |
| Isoform distribution (UniProt Q02078: tissue specificity). | UniProt reports MEF2 and MEFA isoforms only in skeletal and cardiac muscle and brain, while RSRFC4 and RSRFC9 were found in all tissues examined (UniProt Q02078: isoforms). Thus, broad HPA staining does not by itself identify which isoform an antibody detects; that requires epitope or isoform-specific evidence. |
| Antibody evidence (HPA: antibody validation). | CAB004499 has Approved IHC status, while HPA046597 and HPA056563 have Supported ICC status with no IHC status supplied (HPA: antibodies). HPA calls the tissue pattern Approved with medium staining–RNA consistency (HPA: tissue IHC). Review the IHC result in that evidence context rather than treating an ICC validation as IHC validation. |
| IF/ICC Q&A: where should MEF2A appear? | Mainly in the nucleoplasm (HPA: supported ICC-IF localisation). HPA additionally lists cytosol as uncertain (HPA: subcellular), so a cytosolic IF signal needs cautious interpretation. The supplied IF evidence informs localisation; it supplies no IF/ICC protocol option for this IHC page. |
| Retrieval, detection, and modifications (general IHC practice; UniProt Q02078: modified residues). | Antigen retrieval and chromogenic detection settings can affect an IHC assay in general (general IHC practice). UniProt lists phosphorylation and acetylation sites, but the supplied records do not map an antibody epitope to them or report MEF2A-specific retrieval or fixation sensitivity (UniProt Q02078: modified residues). |
| Situation | Likely cause | Next action |
|---|---|---|
| The known-positive section lacks nuclear staining (HPA: High in heart cardiomyocytes). | The assay may have insufficient signal, or its detection steps may have failed (general IHC practice); this observation alone does not identify the failed step. | Check that the positive-control tissue and expected cells are present, then review antibody use, retrieval, detection reagents, and control performance (general IHC practice). Avoid calling the test sample negative until the positive control works. |
| Most colour lies outside nuclei (HPA: general nuclear expression). | Non-specific staining or detection background is possible (general IHC practice). HPA’s uncertain cytosolic ICC-IF observation does not establish a predominantly cytoplasmic paraffin IHC pattern (HPA: subcellular). | Compare cell outlines with the counterstain and a negative control; review blocking and detection conditions if colour persists without matching nuclei (general IHC practice). |
| Liver cholangiocytes or stomach glandular cells stain strongly (HPA: Not detected in both). | Cross-reactivity or endogenous detection activity may explain an unexpected chromogenic signal (general IHC practice). HPA’s reported absence is an assay observation, not an absolute biological exclusion (HPA: tissue IHC). | Check a negative detection control and compare nuclear localisation with a reported positive tissue before attributing that staining to MEF2A (general IHC practice; HPA: general nuclear expression). |
| The whole section looks hazy, obscuring nuclei (HPA: general nuclear expression). | Excess primary antibody, incomplete blocking, or detection background can obscure cell-level interpretation (general IHC practice). The supplied sources give no MEF2A-specific background mechanism. | Review the antibody dilution against its own IHC instructions, blocking, washes, and negative control; reassess whether discrete nuclear staining remains (general IHC practice). No dilution is specified in the supplied evidence. |
| Some cells in one tissue stain while nearby cells do not (HPA: cell-level tissue IHC). | HPA reports staining by cell type: for example, adipocytes are High in adipose tissue, whereas colon endothelial cells are Low (HPA: tissue IHC). Mixed staining need not mean that every cell failed. | Identify the stained cell type and score nuclear signal by cell population; compare each population with the corresponding HPA observation rather than scoring the whole section as one unit (HPA: tissue IHC; general IHC practice). |
| An ICC-supported antibody gives an ambiguous paraffin section result (HPA: antibodies). | Supported ICC status for HPA046597 or HPA056563 does not supply an IHC validation status (HPA: antibodies). Assay formats can yield different results (general IHC practice). | Review IHC-specific antibody validation and use an appropriate positive tissue and negative control for the paraffin assay (general IHC practice; HPA: High in heart cardiomyocytes). |
Experiment evidence
IHC & IF images showing MEF2A staining
PB9953 · IHCIHC analysis of MEF2A using anti-MEF2A antibody (PB9953). MEF2A was detected in a paraffin-embedded section of mouse brain tissue. Heat medi
PB9953 · IHCIHC analysis of MEF2A using anti-MEF2A antibody (PB9953). MEF2A was detected in a paraffin-embedded section of rat brain tissue. Heat mediat
PB9953 · IFIF analysis of MEF2A using anti-MEF2A antibody (PB9953). MEF2A was detected in immunocytochemical section of U20S cells. Enzyme antigen retr
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000068305-MEF2A/tissue/cerebral+cortex#imid_1409204
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000068305-MEF2A/tissue/colon#imid_1409138
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000068305-MEF2A/tissue/liver#imid_1409123
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000068305-MEF2A/tissue/kidney#imid_1409140
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA046597; green = MEF2A, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA046597; green = MEF2A, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MEF2A IHC & IF
🧪Run cerebellum first: cells in the granular layer should stain (HPA: High in cells in the cerebellar granular layer). Use liver cholangiocytes as the negative tissue (HPA: Not detected in liver cholangiocytes); on the cerebellum slide, treat unstained neighboring cells as background comparators, without assuming a particular cell type is MEF2A-negative.
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: Liver (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MEF2A in A-431, U-251MG, U2OS, HEL, NIH 3T3, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched nonimmune rabbit IgG isotype control for the rabbit primary (caption: rabbit anti-MEF2A antibody). Use MEF2A knockout material as a biological negative where available; for the caption’s biotin-based DAB method, control endogenous biotin and peroxidase activity (caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: The selected paraffin-section mouse brain caption reports heat retrieval in EDTA at pH 8.0 but does not report a fixative, a target-specific fixation window or a fixation effect (caption: mouse brain paraffin section; fixative unreported). Paraffin IHC is directly documented; the supplied evidence does not establish that frozen sections or IF are easier, although ICC-IF images support nucleoplasmic localization (HPA: nucleoplasm supported). Check biotin-based brain staining against the controls before scoring nuclei (caption: SABC and DAB; HPA: nucleoplasm supported).
HPA tissue IHC evidence for MEF2A
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
Section 3
Advanced MEF2A IHC Tips
Troubleshoot MEF2A staining in paraffin sections by checking retrieval, nuclear localisation, cell identity and matched controls before interpreting intensity.
Which retrieval conditions should I start with for weak MEF2A staining?
Start with heat-mediated retrieval in EDTA at pH 8.0 for the catalog antibody in paraffin sections (datasheet PB9953). The selected mouse brain example used this retrieval before incubation with 1 μg/ml primary antibody overnight at 4°C (caption PB9953). If nuclear staining is weak, adjust heating duration within the retrieval system’s recommended range, then compare sections processed together (standard IHC practice). Record tissue integrity alongside signal, because excessive heating can damage morphology and make nuclear scoring unreliable (standard IHC practice). Hold detection conditions constant while changing retrieval so the source of any improvement is clear (standard IHC practice).
Could fixation explain weak or uneven MEF2A staining?
The selected tissue image identifies a paraffin section but does not state its fixative, so MEF2A sensitivity to fixation is unknown for this antibody (caption PB9953). Record fixative, fixation duration and processing history for each section before comparing staining intensity (standard IHC practice). Compare sections with matched processing and apply the same EDTA pH 8.0 heat retrieval used in the selected example (datasheet PB9953; standard IHC practice). If staining varies across a section, inspect morphology and processing quality before changing antibody concentration (standard IHC practice). Treat an apparent fixation effect as a hypothesis until matched specimens show a reproducible difference (standard IHC practice).
How should I evaluate cytoplasmic staining when MEF2A is expected in nuclei?
Score nuclear staining as the primary localisation because MEF2A is annotated as nuclear and HPA reports a supported nucleoplasmic location (UniProt Q02078 subcellular; HPA subcellular). HPA also reports cytosol as an uncertain additional location, so cytoplasmic signal alone cannot establish MEF2A localisation (HPA subcellular). Compare cytoplasmic intensity with matched nuclear staining, tissue morphology and a primary-antibody omission control (standard IHC practice). Apply the same compartment criteria across sections, particularly when chromogen deposits obscure nuclear boundaries (standard IHC practice). Record mixed patterns separately rather than folding cytoplasmic staining into a nuclear MEF2A score (standard IHC practice).
Can this stain distinguish MEF2A isoforms or modified MEF2A?
Do not assign a stained nucleus to a particular isoform without a documented antibody epitope and isoform-specific validation (standard IHC practice). MEF2A has 8 listed isoforms, and their reported tissue distributions differ (UniProt Q02078 isoforms and tissue specificity). Its MADS-box spans residues 3–57, while listed modified residues include phosphorylation and acetylation sites elsewhere in the sequence (UniProt Q02078 domains and modified residues). These features make epitope location relevant when interpreting staining, but the supplied caption does not define this antibody’s epitope (UniProt Q02078 domains and modified residues; caption PB9953). Report the result as antibody-detected MEF2A staining unless separate evidence establishes isoform or modification selectivity (standard IHC practice).
How would I check a MEF2A finding with multiplex immunofluorescence?
Use immunofluorescence as an orthogonal check on the paraffin-section IHC result, scoring MEF2A against a nuclear counterstain and a marker for the expected cell type (standard IF practice). For example, choose a validated cardiomyocyte marker when examining heart muscle, where HPA reports high cardiomyocyte staining (HPA: High in heart muscle cardiomyocytes; standard IF practice). Choose fluorophores after inspecting unstained tissue for autofluorescence, and include single-stain controls to assess channel bleed-through (standard IF practice). MEF2A has no transmembrane segment and is primarily nuclear, so permeabilisation must permit antibody access to intracellular nuclear antigen (UniProt Q02078 topology and subcellular; standard IF practice). Optimise IF fixation and permeabilisation independently; the paraffin-section caption supplies no IF fixation condition (caption PB9953; standard IF practice).
What should I check when DAB obscures MEF2A-positive nuclei?
The selected paraffin-section example used a biotinylated secondary, avidin–biotin detection and DAB, so assess background within that detection workflow (caption PB9953). Include a primary-antibody omission control and check whether deposits persist in the same tissue compartments (standard IHC practice). Apply a peroxidase block and, when using biotin-based detection, evaluate endogenous biotin as potential sources of signal (standard IHC practice). The example used 10% goat serum blocking and 1 μg/ml primary antibody overnight at 4°C (caption PB9953). If background remains, titrate the primary and shorten chromogen development while keeping retrieval and control sections matched (standard IHC practice).
How should I quantify MEF2A across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and score nuclear staining, consistent with MEF2A’s nuclear annotation and HPA’s supported nucleoplasmic localisation (UniProt Q02078 subcellular; HPA subcellular). Use the percentage of positive nuclei or a nuclear H-score that combines positive-cell fraction with intensity; report the scoring thresholds (standard IHC practice). Normalise counts to the number of eligible nuclei, or report positive-cell density per mm² of viable tissue when cell counts are impractical (standard IHC practice). Keep retrieval, staining batch, exposure conditions for image capture and analysis settings consistent across comparisons (standard IHC practice). Exclude damaged or necrotic regions by a predefined rule and retain compartment-specific scores (standard IHC practice).
Which findings support a true MEF2A-positive IHC result?
A plausible result is nuclear staining in intact cells, consistent with MEF2A’s nuclear annotation and HPA’s general nuclear tissue profile (UniProt Q02078 subcellular; HPA tissue IHC). HPA reports high staining in cerebellar granular-layer cells and heart muscle cardiomyocytes, providing tissue and cell context for evaluating a positive pattern (HPA: High in cerebellum granular-layer cells and heart muscle cardiomyocytes). Compare candidate positives with the primary-antibody omission control and inspect tissue edges and necrotic regions for nonspecific deposits (standard IHC practice). Diffuse staining in the wrong compartment or cell population needs independent validation before biological interpretation (standard IHC practice). Exclude residual endogenous peroxidase signal when interpreting DAB staining (standard IHC practice).
Boster reagents
Best MEF2A / Myocyte-specific enhancer factor 2A IHC Antibodies
PB9953 has IHC images from paraffin sections of mouse and rat brain and human glioma and meningioma, plus an ICC/IF image of U20S cells (PB9953 image captions).
Real IHC data
Anti-MEF2A Antibody ®
Cat # PB9953
PB9953 is the SKU that renders, with its own mouse brain paraffin-section IHC figure (PB9953 card figure). Additional captions document rat brain, human glioma and human meningioma IHC, and U20S cell ICC/IF (PB9953 image captions).
Which to pick: Choose PB9953 for tissue IHC: its paraffin-section captions describe EDTA retrieval at pH 8.0 and 1 μg/ml primary antibody; the fixative is unreported (PB9953 IHC image captions). For IF/ICC, PB9953 has a U20S cell image, while rabbit monoclonal M01398-1 lists ICC/IF but has no supplied image (PB9953 IF image caption; M01398-1 catalog). For work across human, mouse and rat, both list those species, but PB9953 also lists IHC and has paraffin-section images from all three; M01398-1 does not list IHC (PB9953 catalog and IHC image captions; M01398-1 catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q02078 (MEF2A_HUMAN, Myocyte-specific enhancer factor 2A).
- Human Protein Atlas. MEF2A tissue IHC expression (reliability: Approved).
- Human Protein Atlas. MEF2A subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. MEF2A antibody validation summary (3 antibodies).
- Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494. Molecular therapy. Nucleic acids 2017 — PMC5415962.
- Maternal high-fat diet orchestrates offspring hepatic cholesterol metabolism via MEF2A hypermethylation-mediated CYP7A1 suppression. Cellular & molecular biology letters 2024 — PMC11654142.
- Histopathological and epigenetic changes in myocardium associated with cancer therapy-related cardiac dysfunction. ESC heart failure 2022 — PMC9715834.
- Houttuynia cordata Thunb Promotes Activation of HIF-1A-FOXO3 and MEF2A Pathways to Induce Apoptosis in Human HepG2 Hepatocellular Carcinoma Cells. Integrative cancer therapies 2017 — PMC5759946.
- PubMed PMID:1748287 — UniProt-cited evidence.
- PubMed PMID:1516833 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MEF2A (Myocyte-specific enhancer factor 2A). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9953). Validated IHC antibody: PB9953 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative Liver. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse brain tissue; fixative not specified (datasheet PB9953); 2. Fixation: Image fixative and duration unreported (datasheet PB9953); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9953); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9953); 8. Primary antibody: Rabbit anti-MEF2A, 0.5-1μg/ml (datasheet PB9953); 9. Primary incubation: Overnight at 4 °C (datasheet PB9953). Watch for: Fixation: Keep fixation consistent between sections (standard IHC practice; not target-specific); Caveat: Staining shows medium agreement with RNA (HPA tissue IHC); Isoform / epitope: 8 isoforms; antibody epitope coverage is unreported (UniProt; datasheet PB9953); Regulation: MEF2/MEFA: skeletal muscle, heart, brain (UniProt). Evidence: UniProt Q02078, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet PB9953, PMC5415962, PMC11654142. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MEF2A/immunohistochemistry-ihc-guide.